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Background: Treatment of multidrug resistant tuberculosis (MDR-TB) is lengthy, toxic, expensive, and has generally poor
outcomes. We undertook an individual patient data meta-analysis to assess the impact on outcomes of the type, number,
and duration of drugs used to treat MDR-TB.
Methods and Findings: Three recent systematic reviews were used to identify studies reporting treatment outcomes of
microbiologically confirmed MDR-TB. Study authors were contacted to solicit individual patient data including clinical
characteristics, treatment given, and outcomes. Random effects multivariable logistic meta-regression was used to estimate
adjusted odds of treatment success. Adequate treatment and outcome data were provided for 9,153 patients with MDR-TB
from 32 observational studies. Treatment success, compared to failure/relapse, was associated with use of: later generation
quinolones, (adjusted odds ratio [aOR]: 2.5 [95% CI 1.1–6.0]), ofloxacin (aOR: 2.5 [1.6–3.9]), ethionamide or prothionamide
(aOR: 1.7 [1.3–2.3]), use of four or more likely effective drugs in the initial intensive phase (aOR: 2.3 [1.3–3.9]), and three or
more likely effective drugs in the continuation phase (aOR: 2.7 [1.7–4.1]). Similar results were seen for the association of
treatment success compared to failure/relapse or death: later generation quinolones, (aOR: 2.7 [1.7–4.3]), ofloxacin (aOR:
2.3 [1.3–3.8]), ethionamide or prothionamide (aOR: 1.7 [1.4–2.1]), use of four or more likely effective drugs in the initial
intensive phase (aOR: 2.7 [1.9–3.9]), and three or more likely effective drugs in the continuation phase (aOR: 4.5 [3.4–6.0]).
Conclusions: In this individual patient data meta-analysis of observational data, improved MDR-TB treatment success and
survival were associated with use of certain fluoroquinolones, ethionamide, or prothionamide, and greater total number of
effective drugs. However, randomized trials are urgently needed to optimize MDR-TB treatment.
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Introduction
The increasing incidence of multidrug resistant tuberculosis
(MDR-TB), defined as resistance to at least isoniazid and rifampin,
is a major concern for TB control programs worldwide. MDR-TB
treatment requires prolonged use of multiple second-line anti-TB
drugs, which are more expensive and toxic than first-line drugs, yet
less efficacious [1]. As a result of these problems, administration of
MDR-TB treatment imposes substantial operational challenges in
resource constrained settings. Further, the optimal composition and
duration of MDR-TB treatment regimens is uncertain [1,2].
Three systematic reviews have recently examined determinants
of treatment outcomes in MDR-TB [3–5]. However, these three
reviews identified no randomized trials, and the majority of the
observational studies identified reported results with individualized
treatment. There were considerable differences between studies in
the diagnostic methods used, treatment regimens given, and clinical
characteristics of the patient populations. As a result, these meta-
analyses could only analyze pooled odds of treatment success
associated with proportions of patients with specific clinical
characteristics or receiving specific treatments. This approach has
considerable limitations for a clinical problem of this complexity.
Even in the absence of randomized trials, an individual patient
data meta-analysis of observational data offers potential benefits.
Detailed patient level information can be used to estimate
associations of treatment factors with outcomes, stratified by
IPD Meta-analysis of MDR-TB Treatment
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covariates in meta-regression. We conducted an individual patient
data meta-analysis using patient level data combined from
different centers, using methods suggested by the Cochrane group
[6]. We addressed several questions formulated by an expert
committee of the World Health Organization (WHO) responsible
for revision of guidelines for treatment of MDR-TB [7]. These
questions included the impact of specific drugs, number of drugs,
and duration of treatment on clinical outcomes of patients with
pulmonary MDR-TB.
Figure 1. Study selection.
doi:10.1371/journal.pmed.1001300.g001
IPD Meta-analysis of MDR-TB Treatment
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Selection of Studies
The studies considered for this individual patient data meta-
analysis were identified from published original studies included in
three recent systematic reviews of MDR-TB treatment outcomes
[3–5]. All three reviews included studies published after 1970 that
reported original data of treatment of patients with microbiolog-
ically confirmed MDR-TB. Additional specific criteria for this
meta-analysis were: the study authors could be contacted and were
willing to share their data; the cohort included at least 25 subjects
treated for MDR-TB; and, at least treatment success, as defined
below, was reported. Patients within these datasets were excluded
if they had only extra-pulmonary TB, had extensive drug
resistance (XDR-TB, as defined elsewhere [8]), or were missing
treatment information.
Data Sharing, Extraction, and Verification
Letters describing the meta-analysis were communicated to all
corresponding authors of eligible studies. The McGill investigators
signed formal data sharing agreements with all collaborating
investigators regarding sharing of results, publications, and
‘‘ownership’’ of the data. This project was approved by the
Research Ethics Board of the Montreal Chest Institute, McGill
University Health Centre, and when deemed necessary by local
ethics boards of originally approved studies.
Each author provided center-level information such as diag-
nostic laboratory methods, treatment regimen doses and supervi-
sion, and outcome definitions. Regimens were considered individ-
ualized if regimens were tailored to individual patients’
characteristics such as prior therapy, or drug susceptibility testing
(DST) results. Authors also provided de-identified patient level
information including age, sex, HIV infection, site of disease,
results of chest x-ray, acid fast bacilli (AFB) smear, culture, and
DST for first and second-line drugs, drugs used and duration for
initial and continuous phases of treatment, surgical resection, and
outcomes, including adverse events that required a change in
therapy. Treatment outcome definitions provided by each author
were compared to the consensus definitions published by Laserson
et al. [9], and rated as the same, closely similar, or not similar.
These definitions are summarized at the top of Table S3. Relapse
was any recurrence of disease after successful treatment comple-
tion, and was combined with failure for all analyses. For this
analysis we considered the following as part of group 5 drugs:
amoxicillin-clavulanate, macrolides (azithromycin, roxithromycin,
and clarithromycin), clofazimine, thiacetazone, imipenem, line-
zolid, high dose isoniazid, and thioridazine.
Authors were contacted to request additional data and clarify
variable definitions and coding. Variables from each original
dataset were extracted, their meaning and coding verified, then
mapped to a common set of variables for all patients. Hence
datasets from each center had the same variables for all patients,
but each dataset was kept distinct. As a final verification, the
clinical characteristics of each study population were compared
with the original published papers.
Data Analysis
We considered three types of drug-exposure in our meta-
analysis: (i) specific drugs administered (grouped as suggested by
WHO [1]), (ii) duration of treatment regimen, and (iii) number of
likely effective drugs used. Drugs were considered likely effective if
susceptible on drug susceptibility testing, regardless of history of
prior use. We estimated odds of treatment success (defined as
treatment cure or completion) compared to one of three alternate
outcomes: (i) treatment failure or relapse; (ii) treatment failure,
relapse or death; and (iii) treatment failure, relapse, death or default.
For duration of therapy, comparisons (ii) and (iii) were not
Table 1. Clinical characteristics and treatment received of
patients included in the analysis.
Demographic Characteristics Data Data Data
Mean age in years (SD) (25 missing) 38.7 (13.6) — —
Male sex (%) (three missing) 6,280 (69%) — —
Clinical characteristics Yes No Missing
AFB – smear positive (n, %) 6,012 (66%) 1,878 (21%) 1,263 (14%)
Cavities on x-ray (n, %) 4,723 (52%) 2,019 (22%) 2,411 (26%)
Extensive disease (n, %) 6,753 (74%) 2,226 (24%) 174 (2%)
HIV positive (n, %) 1,077 (12%) 6,805 (74%) 1,271 (14%)
Pulmonary TB only (n, %) 8,713 (96%) 232 (2%) 208 (2%)
Prior TB therapy (any) 6,683 (73%) 2,027 (22%) 443 (5%)
Prior therapy with second-line drugs 942 (10%) 7,455 (82%) 756 (8%)
Resistance to other drugs Sensitive Resistant Not tested
Ethambutol (n, %) 2,736 (30%) 4,065 (44%) 2,352 (26%)
Pyrazinamide (n, %) 2,406 (26%) 2,443 (27%) 4,304 (47%)
Streptomycin (n, %) 2,454 (27%) 4,154 (45%) 2,545 (28%)
Treatment received
Rifabutin (n, %) 130 (1.4%) — —
Ethambutol (n, %) 4,722 (52%) — —
Pyrazinamide (n, %) 6,571 (72%) — —
Ciprofloxacin (n, %) 986 (11%) — —
Ofloxacin (n, %) 6,489 (71%) — —
Later generation quinolones (n, %) 1,258 (14%) — —
Streptomycin (n, %) 1,326 (14%) — —
Kanamycin (n, %) 5,002 (55%) — —
Amikacin (n, %) 428 (5%) — —
Capreomycin (n, %) 1,757 (19%) — —
Ethionamide (n, %) 3,873 (42%) — —
Prothionamide (n, %) 3,709 (41%) — —
Cycloserine (n, %) 5,344 (58%) — —
Para-aminosalicylic acid (PAS) (n, %) 3,196 (33%) — —
One group 5 drug 2,115 (23%) — —
Two or more group 5 drugs 594 (7%) — —
Outcomes (mutually exclusive)
Success (cure and treatment
completed)
4,934 (54%) — —
Failure 645 (7%) — —
Relapse 87 (1%) — —
Default, transfer out, unknown 2,095 (23%) — —
Died during MDR-TB treatment 1,392 (15%) — —
Percentages are of all 9,153 patients. Extensive disease defined as AFB-smear
positive, or cavities on chest x-ray if no information about AFB-smear. Prior TB
therapy: defined as treatment with any, or second-line TB drugs for 1 mo or
more. Later generation quinolones included levofloxacin, moxifloxacin,
gatifloxacin, and sparfloxacin. Cycloserine included terizidone—a dimer of D-
cycloserine given in some centers. Drugs analysed as group 5 included:
amoxicillin-clavulanate, macrolides (azithromycin, roxithromycin,
clarithromycin), clofazimine, thiacetazone, imipenem, linezolid, high dose INH,
and thioridazine. Relapse ascertained in only 2,261 patients (14 cohorts).
SD, standard deviation.
doi:10.1371/journal.pmed.1001300.t001
IPD Meta-analysis of MDR-TB Treatment
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planned duration was not recorded—only the actual duration,
which was truncated by default or death during treatment.
We used random effects (random intercept and random slope)
multi-variable logistic regression estimated via penalized quasi-
likelihood (Proc Glimmix in SAS [10]) in order to estimate the
adjusted odds and 95% CIs of treatment success associated with
different treatment covariates [11–13]. As a sensitivity analysis, all
models for primary analyses were also estimated using adaptive
quadrature (QUAD) [14]. Patients were considered as clustered
within studies and intercepts and slopes of the main exposure
variables were allowed to vary across studies; this is to account for
otherwise unmeasured inter-study differences in patient popula-
tions, as well as center-specific differences in data ascertainment,
Figure 2. Treatment success versus failure and relapse and death. Crude treatment success versus failure or relapse or death by study with
exact 95% CI, as well as number of subjects with success and number of subjects treated. Fixed and der Simonian and Laird random effects pooled
estimates are given (purple dots). Two studies that used only first-line TB drugs are indicated by a red square.
doi:10.1371/journal.pmed.1001300.g002
IPD Meta-analysis of MDR-TB Treatment
PLOS Medicine | www.plosmedicine.org 5 August 2012 | Volume 9 | Issue 8 | e1001300Figure 3. Treatment success versus failure and relapse and death. Fixed and der Simonian and Laird random effects pooled estimates are
given (purple dots). Two studies that used only first-line TB drugs are indicated by a red square.
doi:10.1371/journal.pmed.1001300.g003
IPD Meta-analysis of MDR-TB Treatment
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intercepts (here the baseline log odds of success in each cohort) and
slopes (here treatment efficacy) were interpreted to indicate how
much these varied across the studies. We report the average
estimate of effect across studies from these models and the
estimated inter-study variability and standard deviation of that
variance, as well as the variance of the intercept and the standard
deviation of that variance.
Estimates of effect of each treatment parameter for each dataset
were adjusted for five covariates: age, gender, HIV co-infection,
extent of disease (considered extensive if AFB smear positive, or if
AFB smear information was missing, then if there was cavitation
on chest x-ray), and past history of TB treatment (a three level
variable—no previous TB treatment, previous TB treatment with
first-line drugs, and previous treatment with second-line drugs).
Analyses were performed in all patients and in subgroups—
stratified or restricted by important covariates. We tested for the
interaction between previous treatment with second-line TB drugs
and the number of drugs and duration of treatment in the
intensive and continuation phases, respectively. In secondary
analyses we included more than one treatment parameter (up to
four drugs at once), and individual drugs with treatment duration.
For the multivariable analyses only, missing values of these five
clinical covariates were imputed using means of patients at the
same center with non-missing information. Sex was missing in
three patients, age was missing in 27, HIV was missing in
1,271(14%), history of past TB treatment missing in 443 (5%),
history of past second-line drug use 758 (8%), and extent of disease
information missing in 174 (2%). We assessed whether findings
were altered when missing values were estimated using a different
method of probabilistic imputation, in secondary analysis [15].
Additionally, heterogeneity was explored visually using Forest
plots of study specific estimates, and estimated quantitatively via
the I
2 and its associated 95% CI [13]. For these analyses, estimates
of effect were calculated separately for each study, adjusting for
relevant patient-level covariates, and pooled using conventional
meta-analytic techniques. All analysis was performed using SAS,
version 9.2 (SAS Institute).
Results
Selection of Studies and Description of the Study
Population
We identified 67 unique cohorts from the three previous
systematic reviews of MDR-TB. Of these, 35 datasets were not
used for reasons summarized in Figure 1, leaving 32 datasets with
information on 9,898 patients [16–57]. From these we excluded
410 patients with XDR, 208 with inadequate treatment informa-
tion, and 127 with solely extra-pulmonary TB, leaving 9,153
individual patients analyzed; their clinical characteristics and
outcomes are summarized in Table 1.
The included studies originated from 23 countries, from all
WHO health regions. Final sample sizes included in the analysis
ranged from 18 to 2,174 patients. In the supplement are
summarized: study and center characteristics (Table S1a),
excluded studies (Table S1b), doses of drugs commonly used
(Table S2), and outcome definitions—the accepted standards and
those used in each series (Table S3). Treatment was individualized
in 26 studies with 5,985 patients, and standardized in six studies
with 2,968 patients. A total of 200 patients in two centers received
standardized regimens with first-line drugs only; all remaining
patients received second-line drugs. In all but one study, the
outcome definitions for treatment success and failure were judged
the same or similar to the consensus definitions [9]. Overall 4,934
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failed or relapsed, 1,392 (15%) died, and 2,095 (23%) defaulted
(Table 1). Pooled treatment success, compared to failure/relapse/
death, was 75% but varied widely between studies (Figure 2), while
pooled success, compared to fail/relapse/death and default was
only 54% (Figure 3). Adverse drug reactions that resulted in
changed therapy occurred in 1932 (21%), and 499 (5%) patients
underwent pulmonary resection surgery. Patients who died were
significantly older, more likely to be HIV co-infected, with more
extensive disease, and/or had prior therapy—with first-line and
particularly with second-line TB drugs. Those who defaulted were
significantly older, and more likely to have HIV co-infection (data
not shown in tabular form).
Treatment Correlates of Outcomes
As seen in Table 2, the use of later generation quinolones, or
ofloxacin, or ethionamide/prothionamide, as part of multidrug
regimens, was significantly associated with treatment success
compared to failure or relapse. The use of these same drugs, as
well as pyrazinamide or cycloserine were significantly associated
with treatment success compared to failure, relapse, or death,
while the use of later generation quinolones, ofloxacin, ethion-
amide/prothionamide or kanamycin were significantly associated
with treatment success compared to failure, relapse, death, or
default. Treatment outcomes of the 594 patients who received two
or more group 5 drugs were significantly worse than the 2,115
patients who received one group 5 drug, whose outcomes were, in
turn, worse than those of the 6,444 patients who received none of
these drugs. Since this finding likely reflected confounding by
indication for use of these drugs (i.e., group 5 drugs were used
more often in patients with more severe disease or worse
resistance), the analysis of the four most commonly used group 5
drugs—amoxicillin-clavulanate, macrolides, clofazimine, and thi-
acetazone—was restricted to patients who received only one group
5 drug. This revealed that none of these four drugs, compared to
the others, was associated with significantly superior treatment
outcomes. There was often significant heterogeneity in baseline
odds of treatment success and in the treatment effect (as seen in the
large variance relative to its standard deviation for the intercept
and slope, respectively; these are provided in detail in Table S9.)
Patients with prior treatment with second-line drugs were
significantly less likely to have HIV co-infection, but were more
likely to have cavitary disease, and strains with resistance to other
first-line drugs (Table S4). In these patients the odds of treatment
success with the individual drugs were similar, although CIs were
broad (Table S5).
As shown in Table 3, compared to use of three or fewer likely
effective drugs in the initial intensive phase, the odds of success
were significantly greater with use of four drugs, and were very
similar with use of five, six, or more drugs (Table 3). In the
continuation phase, compared to use of two or fewer likely
effective drugs, use of three drugs was associated with significantly
superior odds of success, which were similar to the odds of success
with use of four, or five or more likely effective drugs (Table 3).
Fewer patients were included in these analyses because only a
subset of studies provided information on the number of likely
effective drugs used in the initial intensive phase (18 studies) or the
continuation phase (15 studies). In patients with prior treatment
with second-line drugs the maximal odds of success was seen with
five likely effective drugs in the initial intensive phase (Table 4),
and five drugs in the continuation phase (Table 4). There was
substantial heterogeneity and a statistically significant interaction
between prior treatment with second-line drugs and number of
drugs used in the continuation phase (p=0.01), and in the initial
intensive phase (p=0.05) (Tables S10). In further exploratory
analyses, there was no association between the number of drugs
Table 3. Association of number of likely effective drugs with treatment success—during different phases of treatment.
n Likely Effective Drugs – All
Patients – Three Analyses
All Patients – Success Versus Fail/
Relapse
All Patients – Success Versus
Fail/Relapse/Death
All Patients – Success Versus Fail/Relapse/
Death/Default
n aOR (95% CI) n aOR (95% CI) n aOR (95% CI)
Initial intensive phase
0–2 118 1.0 (reference) 277 1.0 (reference) 322 1.0 (reference)
3 161 1.1 (0.5–2.4)
a 250 1.7 (1.2–2.5)
a 316 1.2 (0.8–1.8)
a
44 6 8 2.0 (1.1–3.6)
a 542 2.7 (1.9–3.9)
a 671 1.9 (1.3–2.9)
a
58 1 4 2.0 (1.1–3.6)
a 900 2.8 (1.7–4.6)
a 1,114 1.9 (1.2–3.0)
a
6+ 811 2.4 (1.0–5.4)
a 977 2.1 (1.4–3.1)
a 1,185 1.4 (1.0–2.1)
a
Continuation phase
0–2 254 1.0 (reference) 531 1.0 (reference) 633 1.0 (reference)
35 5 2 2.5 (1.6–4.0)
b 635 5.7 (3.4–9.7)
a 759 4.9 (2.7–8.7)
a
45 9 8 2.8 (1.6–4.9)
a 663 5.7 (3.2–10.0)
a 779 4.2 (2.6–6.7)
a
5+ 560 2.0 (0.9–4.2)
a 608 7.0 (5.1–9.7)
b 656 4.9 (2.5–9.5)
a
Likely effective, drugs to which isolate susceptible in laboratory testing. n, number of patients in subgroup of interest. aOR, adjusted for age, sex, HIV, past TB treatment,
past MDR treatment (treatment for more than 1 mo with two or more second-line drugs), and extent of disease. Missing information was imputed for the following
parameters in the following number of patients: Sex was missing in three, age was missing in 27, HIV was missing in 1,271(14%), history of past TB treatment missing in
443 (5%), history of past second-line drug use 758 (8%), and extent of disease information missing in 174 (2%). Success, defined as cure or treatment completion; see
Methods for definitions. Initial intensive phase, period when injectable given. Continuation phase, period when no injectable given. Only 18 studies provided
information regarding drug susceptibility testing and the number of drugs in the initial phase, while only 15 of these described the number of drugs in the continuation
phase. Bold, estimates are significantly different from the reference group.
aVariance of the random intercepts and slopes was low—so heterogeneity not likely to be important.
bVariance of the random intercepts and slopes could not be estimated.
doi:10.1371/journal.pmed.1001300.t003
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PLOS Medicine | www.plosmedicine.org 9 August 2012 | Volume 9 | Issue 8 | e1001300used in the initial phase with default, but default was more
frequent in patients who received more drugs in the
continuation phase (Table S11).
Among those who did not die or default, odds of treatment
success increased with longer duration of the initial intensive
phase up to the duration of 7.0 to 8.4 mo (Table 5), although
CIs were wide for each interval estimate (Figure 4), and
variance estimates were also high (Tables S12). There was no
statistically significant interaction between intensive phase or
total treatment duration and prior treatment with second-line
drugs. Similarly odds of success increased progressively with
longer total duration of therapy up to 24.6–27.5 mo duration.
In patients with prior second-line drug therapy the maximal
odds of success was seen with total duration of 27.6–30.5 mo,
although there were very few patients in each strata, and CIs
were correspondingly wide. As seen in Tables S6–S8,
additional secondary analyses of optimal duration revealed
similar results for: analyses with adjustment for use of four
drugs, in addition to adjustment for the five clinical covariates
used for all other models (Table S6A), patients who received
only one injectable and experienced no injectable-related
adverse events (Table S6B), or patients who received regimens
containing at least one second-line drug (Table S6C). In
patients who received later generation quinolones the maximal
odds of success was seen with a shorter duration of total
therapy (Table S6D), although CIs were very wide, and
included 1.0. There was a significant trend toward more
frequent history of prior second-line drug treatment, but lower
HIV prevalence with longer duration of initial intensive phase
(Table S8a) and total duration (Table S8b) and somewhat
greater prevalence of resistance to pyrazinamide, ethambutol,
fluoroquinolones, or second-line injectables with longer initial
intensive or total duration.
As a sensitivity analysis, all analyses reported in Tables 2–4
were repeated using random effects logistic regression estimat-
ed via adaptive quadrature. Results, except where indicated in
the tables, were very similar to those estimated using penalized
quasi-likelihood. In addition analyses using probabilistic
imputation for missing values produced very similar results as
results using the imputation methods described above.
Discussion
To our knowledge this is the largest combined analysis of
treatment of MDR-TB, and the first individual patient data
meta-analysis of treatment outcomes in drug resistant TB. With
the detailed individual clinical information for 9,153 patients it
was possible to use stratified, restricted, and/or multivariable
analyses to control for differences in treatment regimens, drug
resistance patterns, prior treatment histories, and other patient
characteristics such as HIV co-infection. Overall treatment
results were poor—treatment success was achieved in only
slightly more than half of all patients. Treatment success was
significantly associated with specific durations, number of likely
effective drugs for the initial intensive and continuation phases
of therapy, and with use of later generation quinolones
(levofloxacin, moxifloxacin, gatifloxacin, and sparfloxacin),
ofloxacin or ethionamide/prothionamide. These results helped
to inform the forthcoming revised MDR-TB treatment
guidelines of WHO, and should be useful in planning therapy
for individual patients.
We suggest cautious interpretation of these results in light of
a number of important limitations. First, we included only 32
studies out of a possible 67 series that had reported outcomes of
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reviews. This selection may have introduced some bias, although
as seen in Table S1b, the characteristics and outcomes of patients
in the included and excluded studies were similar. Second, we
included two studies in which most patients received only first-
line drugs; this may seem obviously inadequate, but earlier
reports supported such treatment [58]. However, only 200
patients were treated in this way, and findings were not changed
when they were excluded from analyses. Third, all the data
included in this review were derived from observational studies,
most of which utilized individualized regimens; this may have
introduced bias if certain drugs, or combinations and durations of
drugs were preferentially used for patients with more extensive
drug resistance, more severe disease, or worse co-morbidities. An
example of this selection bias was the finding that use of any
group 5 drug was associated with worse outcomes, particularly
use of two or more group 5 drugs. As recommended [59], we
controlled this potential confounding by restricting the analysis to
patients who received only one of the group 5 agents. Fourth, the
effects of individual drugs may have been difficult to detect
because of the multidrug composition of all regimens used.
Furthermore certain drugs such as amikacin were used less
often—limiting power—while others, such as linezolid or high
dose isoniazid were used so infrequently they could not be
analyzed. The small size of the ‘‘no-injectable’’ group may have
limited power to detect an impact of the injectables, perhaps
explaining the observed modest effect.
Relapse was ascertained in only 14 studies, which could result in
an over-estimate of treatment success. As seen in Table S7, success
rates were non-significantly lower in centers that did measure
relapse. Finally, since patients included in this analysis were
treated in more than 32 different centers (some studies involved
multiple centers), management differed considerably in terms of
use of hospitalization, response to adverse events, use of adjunctive
surgery, or directly observed therapy, and the resources and
adherence support offered to patients. These unmeasured inter-
center differences could have resulted in bias. For example in
centers that could afford to use later generation fluoro-quinolones,
which are more expensive, there may have been greater resources
to enhance care in other ways. However, the random effects meta-
analytic approach provided some control for these center-level
effects.
This analysis suggests that it would be appropriate to use at least
four likely effective drugs in the initial intensive phase and at least
three likely effective drugs in the continuation phase. However, it
is important to underline that this analysis was restricted to cohorts
of patients in whom drug susceptibility testing was routinely
performed. These results may not apply when standardized
regimens are used without routine drug susceptibility testing. We
had to base analysis of likely effective drugs on drug susceptibility
testing only, because of limited information on the specific drug
regimen for many of the previously treated patients. Hence
caution is warranted given the well-known limitations of drug
susceptibility testing for many of the drugs used, since prior use of
these drugs may increase the likelihood of resistance, even if the
laboratory result indicates susceptibility.
The highest odds of success were associated with duration of
the initial intensive phase of 7–8.4 mo, and with a total duration
of 18–20 mo. However, particular caution should be used for the
interpretation of these results. First we did not have data on
duration of therapy with individual drugs, only the different
phases of treatment. Second, duration of therapy was individu-
Table 5. Association of duration of treatment with success versus failure/relapse—patients grouped by treatment history.
Duration of Treatment
(mo) Intercept All Patients No Prior Second-Line Drug Treatment Prior Second-Line Drug Treatment
n aOR (95% CI) n aOR (95% CI) n aOR (95% CI)
Initial
1–2.4 308 1.0 (reference) 271 1.0 (reference) 6 1.0 (reference)
2.5–3.9 1,406 1.3 (0.5–3.2)
a 1,298 1.5 (0.6–4.2)
b 23 4.2 (0.5–34.3)
b
4.0–5.4 481 2.3 (1.2–4.2)
b 418 2.2 (0.8–6.5)
b 15 10.9 (1.0–117.8)
b
5.5–6.9 377 3.8 (2.0–7.3)
b 314 3.8 (1.8–8.0)
b 26 47.2 (3.0–746.1)
b
7.0–8.4 172 4.8 (1.9–11.8)
b 124 4.9 (1.8–13.5)
b 21 —
8.5–20 792 2.1 (1.2–3.8)
b 517 1.9 (0.6–5.6)
a 228 26.3 (3.8–183.9)
b
Total
6.0–12.5 778 1.0 (reference) 681 1.0 (reference) 33 1.0 (reference)
12.6–15.5 419 1.5 (0.6–3.6)
a 321 1.4 (0.5–4.2)
a 34 0.4 (0.2–1.1)
b
15.6–18.5 1,700 3.6 (1.5–8.7)
a 1,527 3.6 (1.1–11.6)
a 51 2.2 (0.7–6.8)
b
18.6–21.5 655 5.2 (2.0–11.5)
a 34 6.2 (1.8–20.6)
a 40 1.6 (0.6–4.5)
b
21.6–24.5 553 4.9 (2.1–11.5)
b 400 6.3 (2.3–16.8)
b 105 6.5 (2.2–19.7)
b
24.6–27.5 313 11.7 (4.5–30.2)
b 170 12.9 (3.0–56.5)
b 104 8.1 (2.1–31.4)
b
27.6–30.5 160 2.8 (1.0–7.6)
b 89 3.2 (1.0–10.0)
b 53 13.6 (1.6–114.1)
b
30.6–36 89 1.2 (0.2–5.8)
a 36 2.8 (0.4–19.7)
b 38 2.0 (0.6–7.3)
b
n, number of patients in subgroup of interest. aOR, adjusted odds ratios—adjustment described in footnotes for Table 3. Success, defined as cure or treatment
completion and is compared to failure or relapse (see methods for definitions). Other outcomes of death and default not assessed in this analysis because in some
datasets shorter duration that was directly due to death or default could not be identified. Past treatment, prior MDR means past treatment for more than 1 mo with
two or more second-line drugs. No prior MDR includes all other treatment history.
aVariance of the random intercepts and slopes high—so heterogeneity likely important. (See Tables S1–S12 for actual values).
bVariance of the random intercepts and slopes low—so heterogeneity not likely to be important. (See also Tables S1–S12 for actual values).
doi:10.1371/journal.pmed.1001300.t005
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PLOS Medicine | www.plosmedicine.org 11 August 2012 | Volume 9 | Issue 8 | e1001300alized for most patients, based upon severity of disease, prior
therapy, drug resistance patterns, response to therapy, and timing
of sputum conversion. Hence duration of treatment may have
been prolonged in patients with worse disease—as suggested in
Tables S7a and S7b. This could have accounted for the finding
that treatment success was less with very long treatment
durations, although would not be expected to lead to the finding
that the odds of success increased progressively with each interval
of initial intensive phase therapy up to 7–8.5 mo (in fact would be
expected to have the opposite effect). Third, we had limited
information on microbiologic responses, and so could not analyze
the effect of duration after microbiologic conversion—a corner-
stone of current recommendations (although the published
evidence for the relationship between sputum conversion and
long term outcomes in MDR-TB is sparse). As a result
conclusions must be cautious regarding the optimal duration of
therapy, which must balance the burden of prolonged therapy on
patients and health systems, with the possible benefits demon-
strated in this analysis. A recent report from Bangladesh in which
treatment success rates were high with much shorter treatment
[54], underscores the need for appropriately framed randomized
trials to address this issue [60].
Despite these limitations there were a number of important
strengths. A large number of centers, from many different regions
of the world, contributed clinical information on a large number of
individual patients, allowing a detailed and comprehensive
analysis. There was substantial variation in treatment given by
different centers, only partially explained by patients’ character-
istics. In some centers this variation reflected availability of
medications, but in other centers this likely reflected individual
providers’ preferences. This substantial variation in treatment
approach would have been much less likely in patients treated at a
single center, and enhanced our ability to assess the independent
effect of treatment factors on patient outcomes.
Conclusions
This individual patient data meta-analysis of 9,153 patients
suggests that treatment of MDR-TB should include a later
Figure 4. Association of treatment success with duration (adjusted odds and upper bound of CI shown). (A) Duration of initial intensive
phase in all patients (reference group 1.0–2.5 mo). (B) Duration of initial intensive phase—restricted to patients not previously treated with second-
line drugs (reference group 1.0–2.5 mo). (C) Total duration of therapy in all patients (reference group is 6.0–12.5 mo). Patients receiving therapy for
less than 6 or more than 36 mo excluded from analysis. Note: For duration of 24.6–27.5 mo the upper limit of the CI was 30.2. This is truncated at 21.
(D) Total duration of therapy—analysis restricted to patients not previously treated with second-line drugs (reference group is 6.0–12.5 mo. Patients
receiving therapy for less than 6 or more than 36 mo excluded from analysis). Note: For duration of 24.6–27.5 mo, the upper limit of the CI was 56.5.
This is truncated at 21.
doi:10.1371/journal.pmed.1001300.g004
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patients who have not received second-line drugs before, the
optimal number of likely effective drugs appears to be at least four
in the initial intensive phase, and at least three in the continuation
phase. The duration of therapy associated with highest odds of
success was 7–8.5 mo for the initial intensive phase, and 25–27 mo
for total duration. In view of the serious limitations of this
observational data, these findings should be considered to have
highlighted several important questions for future clinical trials.
These questions include the role and choice of injectables, the
optimal duration of an injectable and total therapy, and the
potential value of later generation quinolones as well as certain
group 4 and group 5 drugs. Randomized trials are urgently needed
to address these questions and determine the optimal treatment
regimens for MDR-TB patients.
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Background. In 2010, 8.8 million people developed
tuberculosis—a contagious bacterial infection—and 1.4
million people died from the disease. Mycobacterium
tuberculosis, the bacterium that causes tuberculosis, is spread
in airborne droplets when people with the disease cough or
sneeze and usually infects the lungs (pulmonary tuberculo-
sis). The characteristic symptoms of tuberculosis are a
persistent cough, weight loss, and night sweats. Tuberculosis
can be cured by taking several powerful antibiotics regularly
for at least 6 months. The standard treatment for tubercu-
losis comprises an initial intensive phase lasting 2 months
during which four antibiotics are taken daily followed by a 4-
month continuation phase during which two antibiotics are
taken. However, global efforts to control tuberculosis are
now being thwarted by the emergence of M. tuberculosis
strains that are resistant to several antibiotics, including
isoniazid and rifampicin, the two most powerful, first-line
(standard) anti-tuberculosis drugs.
Why Was This Study Done? Although multi-drug resis-
tant tuberculosis (MDR-TB) can be cured using second-line
anti-tuberculosis drugs, these are more expensive and more
toxic than first-line drugs and optimal treatment regimens
for MDR-TB have not been determined. Notably, there have
been no randomized controlled trials of treatments for MDR-
TB. Such trials, which compare outcomes (cure, treatment
failure, relapse, and death) among patients who have been
randomly assigned to receive different treatments, are the
best way to compare different anti-tuberculosis drug
regimens. It is possible, however, to get useful information
about the association of various treatments for MDR-TB with
outcomes from observational studies using a statistical
approach called ‘‘individual patient data meta-analysis.’’ In
observational studies, because patients are not randomly
assigned to different treatments, differences in outcomes
between treatment groups may not be caused by the
different drugs they receive but may be due to other
differences between the groups. An individual patient data
meta-analysis uses statistical methods to combine original
patient data from several different studies. Here, the
researchers use this approach to investigate the association
of specific drugs, numbers of drugs and treatment duration
with the clinical outcomes of patients with pulmonary MDR-
TB.
What Did the Researchers Do and Find? The researchers
used three recent systematic reviews (studies that use
predefined criteria to identify all the research on a given
topic) to identify studies reporting treatment outcomes of
microbiologically confirmed MDR-TB. They obtained individ-
ual patient data from the authors of these studies and
estimated adjusted odds (chances) of treatment success
from the treatment and outcome data of 9,153 patients with
MDR-TB provided by 32 centers. The use of later generation
quinolones, ofloxacin, and ethionamide/prothionamide as
part of multi-drug regimens were all associated with
treatment success compared to failure, relapse or death, as
were the use of four or more likely effective drugs (based on
drug susceptibility testing of mycobacteria isolated from
study participants) during the initial intensive treatment
phase and the use of three or more likely effective drugs
during the continuation phase. The researchers also report
that among patients who did not die or stop treatment, the
chances of treatment success increased with the duration of
the initial treatment phase up to 7.1–8.5 months and with
the total duration of treatment up to 18.6–21.5 months.
What Do These Findings Mean? These findings suggest
that the use of specific drugs, the use of a greater number of
effective drugs, and longer treatments may be associated
with treatment success and the survival of patients with
MDR-TR. However, these findings need to be interpreted
with caution because of limitations in this study that may
have affected the accuracy of its findings. For example, the
researchers did not include all the studies they found
through the systematic reviews in their meta-analysis (some
authors did not respond to requests for individual patient
data, for example), which may have introduced bias.
Moreover, because the patients included in the meta-
analysis were treated at 32 centers, there were many
differences in their management, some of which may have
affected the accuracy of the findings. Because of these and
other limitations, the researchers note that, although their
findings highlight several important questions about the
treatment of MDR-TB, randomized controlled trials are
urgently needed to determine the optimal treatment for
MDR-TB.
Additional Information. Please access these Web sites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001300.
N The World Health Organization provides information on all
aspects of tuberculosis, including MDR-TB; its guidelines
for the programmatic management of drug-resistant
tuberculosis are available
N The US Centers for Disease Control and Prevention has
information about tuberculosis, including information on
the treatment of tuberculosis and on MDR-TB
N The US National Institute of Allergy and Infectious Diseases
also has information on all aspects of tuberculosis,
including a drug-resistant tuberculosis visual tour
N MedlinePlus has links to further information about
tuberculosis (in English and Spanish)
N TB & ME, a collaborative blogging project run by patients
being treated for multidrug-resistant tuberculosis and
Medecins sans Frontieres, provides information about
MDR-TB and patient stories about treatment for MDR-TB
N The Tuberculosis Survival Project, which aims to raise
awareness of tuberculosis and provide support for people
with tuberculosis, also provides personal stories about
treatment for tuberculosis
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